Smith Brendan 4
4 · CRISPR Therapeutics AG · Filed Oct 18, 2022
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Tax Payment
Common Shares
2022-10-17$55.76/sh−1,111$61,949→ 2,639 total - Exercise/Conversion
Common Shares
2022-10-14+3,750→ 3,750 total - Exercise/Conversion
Restricted Stock Units
2022-10-14+3,750→ 11,250 total→ Common Shares (3,750 underlying)
Footnotes (3)
- [F1]The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on October 14, 2022, (ii) one quarter of the shares shall vest on October 14, 2023, (iii) one quarter of the shares shall vest on October 14, 2024, and (iv) one quarter of the shares shall vest on October 14, 2025.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]On October 14, 2021, the reporting person was granted 15,000 restricted stock units. On October 14, 2022, 3,750 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.